Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

Simple item page
dc.contributor.authorBateman, EDen_ZA
dc.contributor.authorFairall, Len_ZA
dc.contributor.authorLombardi, DMen_ZA
dc.contributor.authorEnglish, Ren_ZA
dc.date.accessioned2015-10-12T10:53:43Z
dc.date.available2015-10-12T10:53:43Z
dc.date.issued2006en_ZA
dc.description.abstractBACKGROUND:To compare the efficacy and safety of budesonide/formoterol (Symbicort(R)) with formoterol (Oxis(R)) in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting beta2-agonist therapy. METHODS: In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma (mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility 2% of predicted normal after inhalation of 400 mug), were randomized to receive either budesonide/formoterol (320/9 mug, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 mug]) or formoterol (9 mug, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 mug]). The primary efficacy variable was the average FEV1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured. RESULTS: FEV1 increased after administration of the study medication in both treatment groups. No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints. There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness. Both treatments were well tolerated. CONCLUSION: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting beta2-agonist.en_ZA
dc.identifier.apacitationBateman, E., Fairall, L., Lombardi, D., & English, R. (2006). Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. <i>Respiratory Research</i>, http://hdl.handle.net/11427/14176en_ZA
dc.identifier.chicagocitationBateman, ED, L Fairall, DM Lombardi, and R English "Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol." <i>Respiratory Research</i> (2006) http://hdl.handle.net/11427/14176en_ZA
dc.identifier.citationBateman, E. D., Fairall, L., Lombardi, D. M., & English, R. (2006). Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res, 7(1), 315.en_ZA
dc.identifier.ris TY - Journal Article AU - Bateman, ED AU - Fairall, L AU - Lombardi, DM AU - English, R AB - BACKGROUND:To compare the efficacy and safety of budesonide/formoterol (Symbicort(R)) with formoterol (Oxis(R)) in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting beta2-agonist therapy. METHODS: In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma (mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility 2% of predicted normal after inhalation of 400 mug), were randomized to receive either budesonide/formoterol (320/9 mug, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 mug]) or formoterol (9 mug, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 mug]). The primary efficacy variable was the average FEV1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured. RESULTS: FEV1 increased after administration of the study medication in both treatment groups. No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints. There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness. Both treatments were well tolerated. CONCLUSION: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting beta2-agonist. DA - 2006 DB - OpenUCT DO - 10.1186/1465-9921-7-13 DP - University of Cape Town J1 - Respiratory Research LK - https://open.uct.ac.za PB - University of Cape Town PY - 2006 T1 - Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol TI - Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol UR - http://hdl.handle.net/11427/14176 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/14176
dc.identifier.urihttp://dx.doi.org/10.1186/1465-9921-7-13
dc.identifier.vancouvercitationBateman E, Fairall L, Lombardi D, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respiratory Research. 2006; http://hdl.handle.net/11427/14176.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDivision of Pulmonologyen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceRespiratory Researchen_ZA
dc.source.urihttp://respiratory-research.comen_ZA
dc.subject.otherRespiratory Researchen_ZA
dc.titleBudesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamolen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bateman_Budesonide_formoterol_2006.pdf
Size:
360.32 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles